Quarterly compliance certificate for dematerialisation filed with BSE, CDSL and NSDL

Compliance View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.1%Reaction day

₹36.82

prior close

₹36.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.8%+2.7% vs market

Pharmaceuticals peers, median of 172sector-2.5%+2.4% vs sector

On the reaction day the stock moved 2.7 pts more than Nifty Microcap 250 and 2.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.1-2.8+2.7-2.5+2.4

Next day

-0.9-2.5+1.6-2.6+1.7

-1.0-1.7+0.7-2.5+1.5

-6.5-1.5-5.0-2.5-4.0

-4.9-0.8-4.1-2.5-2.4

-3.6-2.4-1.2-3.2-0.4

-2.9-3.4+0.4-4.4+1.5

15d

-2.4-8.7+6.4-5.0+2.6

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sandu Pharmaceuticals has submitted a compliance certificate under SEBI Regulation 74(5) for the quarter ended 30 September 2026. The certificate from its registrar MUFG Intime India confirms that securities received for dematerialisation were processed and the depositories names were updated in the register of members within required timelines. This is a routine quarterly regulatory filing sent to BSE, CDSL and NSDL.

Likely market impact

Routine regulatory compliance filing with no material impact on business or shareholders.